Raymond James downgraded Omega Therapeutics (OMGA) to Market Perform from Outperform.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMGA:
- Omega Therapeutics price target lowered to $4 from $9 at Piper Sandler
- Omega Therapeutics provides updated MYCHELANGELO I data
- Omega Therapeutics CEO Mahesh Karande to depart, Kaan Certel to succeed
- Omega Therapeutics reports Q3 revenue $2.61M, consensus $1.34M
- Omega Therapeutics Restructures Leadership and Strategic Focus